Investigational drug · Phase 2
INV-8989
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "INV-8989"
First trial start
2026
Jun 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INV-8989", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advance Solid Tumors
- Colon and Rectal Cancer
- Non - Small Cell Lung Cancer NSCLC
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Ovarian Cancer
- Endometrial Cancer
- Biliary Cancers
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Pancreatic cancer · Endometrial cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "INV-8989" as an intervention, largest first.
Shenzhen Ionova Life Sciences Co., Ltd.Industry
NCT07610798 · 178 participants (planned) · Start Jun 1, 2026 · Primary completion May 2029
Drug: INV-8989 · For: Advance Solid Tumors; Colon and Rectal Cancer; Non - Small Cell Lung Cancer NSCLC and 4 more
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advance Solid Tumors
- JMBI-001Phase 21 trial
Chengdu Anticancer Bioscience, Ltd. · Advance Solid Tumors, Lymphoma, Non-Hodgkin
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.